K. Maeda

New Toxic Metabolites from a Mushroom, Hebeloma vinosophyllum. III. Isolation and Structures of Three New Glycosides, Hebevinosides XII, XIII and XIV, and Productivity of the Hebevinosides at Three Growth Stages of the Mushroom

H. Fujimoto, M. Yamazaki, K. Maeda, 1991 .

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia

Kazuhiro Yoshida, T. Yoshikawa, Yoon-Koo Kang, 2019, JAMA network open.

Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study

T. Satoh, Y. Omuro, T. Nishina, 2018, Gastric Cancer.

Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

M. Taniwaki, S. Iida, K. Tobinai, 2016, Cancer science.

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

E. Juhász, I. Bodrogi, J. Horti, 2008, Cancer Chemotherapy and Pharmacology.

A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors

T. Mukohara, Y. Ando, H. Minami, 2013, Cancer Chemotherapy and Pharmacology.